Moleculin Biotech, Inc. MBRX
NASDAQ · United States · Health Technology
$0.5038+0.00 (+0.68%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refractory acute myeloid leukemiaFull Part A population expected to provide important efficacy insights across subjects who relapsed from or were refractory to first line (1L) AML treatment, including intensive 7+3 and venetoclax-based regimensExpect final Part A dataset to approximate 50/50 between 1L 7+3 and venetoclax-based regimensAbsence of cardiotoxicity continues to di
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits – Independent Cleveland Clinic cardio-oncology evaluation supports continued clinical development of Annamycin as a potentially safer anthracycline HOUSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the publication of a peer-reviewed analysis of the cardia
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.